Septerna's oral PTH1R drug SEP-479 heads into Phase 1 readout for hypoparathyroidism
The healthy-volunteer safety trial will show whether an oral once-daily agonist can mimic PTH biology well enough to compete with Ascendis's injectable in a market it treats today.
Executive Summary
- Septerna's first clinical test of an oral PTH1R agonist is underway in healthy volunteers, aimed at showing the drug can substitute for the daily injections that current hypoparathyroidism treatment requires.
- As a healthy-volunteer safety and pharmacokinetics study, the trial can establish tolerability and a biomarker signal on calcium and PTH levels, not clinical efficacy in patients.
- The nearest comparator is an injectable PTH-replacement therapy already in Phase 3, and no other oral small-molecule PTH1R agonist for this indication is in trials, position that could matter if SEP-479's biomarker data hold up.
- The trial's move to active recruiting with enrollment unchanged at its planned target is a routine early-phase execution step, not a signal of strain.
The trial
Septerna, Inc. (Nasdaq: SEPN) announced on April 13, 2026 that it had dosed the first participants in a Phase 1 trial of SEP-479, a randomized, placebo-controlled single-ascending-dose and multiple-ascending-dose study in healthy adult volunteers. The trial, registered as NCT07433179, targets enrollment of 150 participants, is recruiting in Australia, and carries a primary completion date of February 1, 2027. Its primary endpoint is the frequency of treatment-emergent adverse events; secondary endpoints track SEP-479's plasma pharmacokinetics under single and multiple doses and under fed and fasted conditions. Septerna+1Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule ...Apr 13, 2026A Study to Evaluate Single and Multiple Doses of SEP-479 in Healthy Adult ParticipantsNCT07433179
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What's at stake
Hypoparathyroidism is managed today with either high-dose oral calcium and vitamin D supplements taken several times daily or with injected parathyroid hormone, Septerna Chief Executive Officer Jeffrey Finer said, calling both approaches a burden patients carry over time. SEP-479 is designed as a once-daily oral agonist intended to replace that injection or supplement regimen by directly activating the PTH1R receptor, based on preclinical data showing the compound normalized serum calcium in a rat model of hypoparathyroidism and increased calcium while lowering endogenous PTH in a non-human primate study. SepternaSepterna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule ...Apr 13, 2026
The endpoint bar
Because this is a healthy-volunteer study, the trial can only establish safety, tolerability, and a pharmacokinetic and pharmacodynamic profile, evidenced by changes in endogenous PTH and serum calcium and other biomarkers, not a clinical efficacy claim in patients with the disease. A tolerability signal consistent with the drug's preclinical toxicology profile, which showed the compound was generally well tolerated in 28-day studies across three species, would support advancing SEP-479 into a patient trial. The biomarker readout on calcium and PTH will be the more informative half of the data, since it is the first human test of whether the oral mechanism reproduces the physiology PTH replacement is meant to achieve. SepternaSepterna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule ...Apr 13, 2026
Competitive landscape
Trial activity aimed at PTH1R in hypoparathyroidism has thinned: field-level trial counts for this target-indication pairing fell from 104 in the older period on record to 4 recently. The most advanced program is Ascendis Pharma's palopegteriparatide, an injectable PTH-replacement therapy now in Phase 3 testing at doses above 30 micrograms per day, with a primary completion guided to June 2027. No other oral small-molecule PTH1R agonist appears among active industry trials in this indication, leaving SEP-479 as the only oral entrant tracked against an established injectable standard, a position that would matter only if the Phase 1 biomarker data show the oral mechanism can reach comparable calcium and PTH control.
Operational read
The trial moved from Not yet recruiting to Recruiting status on April 22, 2026, with its enrollment target unchanged at 150 participants, a flat, on-plan progression for an early-phase study. Septerna has repeated the same late-2026-to-early-2027 data guidance across three separate disclosures since the trial's initiation, with no revision to the window. NCT07433179+1A Study to Evaluate Single and Multiple Doses of SEP-479 in Healthy Adult ParticipantsNCT07433179Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule ...Apr 13, 2026
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.